1365267-36-2

Basic information

• Product Name: 1,2-BenzenedicarboxaMide, N1,N2-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]-
• Synonyms: 1,2-BenzenedicarboxaMide, N1,N2-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]-;N1,N2-bis(((S)-2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)phthalamide;Rivaroxaban BenzenedicarboxaMide Impurity;Bis-[Des(5-Chloro-2-carboxythienyl)] Rivaroxaban Phthalamide
• CAS NO: 1365267-36-2
• Molecular Formula: C₃₆H₃₆N₆O₁₀
• Molecular Weight: 712.70524
• Mol File: 1365267-36-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 1106.7±65.0 °C(Predicted)
• Appearance: /
• Density: 1.411±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly, Heated, Sonicated), Methanol (Very Slightly)
• PKA: 13.03±0.46(Predicted)
• CAS DataBase Reference: 1,2-BenzenedicarboxaMide, N1,N2-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-BenzenedicarboxaMide, N1,N2-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]-(1365267-36-2)
• EPA Substance Registry System: 1,2-BenzenedicarboxaMide, N1,N2-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]-(1365267-36-2)

Safety Data

• Hazardous Substances Data: 1365267-36-2(Hazardous Substances Data)

Usage

Uses

Bis-[Des(5-Chloro-2-carboxythienyl)] Rivaroxaban Phthalamide is an impurity of Rivaroxaban (R538000), a novel antithrombotic agent. A highly potent and selective, direct FXa inhibitor.

Upstream product

• 446292-10-0 4-[4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl]morpholine-3-one 
• 1365267-37-3 (S)-2-(((2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)oxazolidin-5-yl)methyl)carbamoyl)benzoic acid 

Relevant articles and documents

PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE

The present invention relates to a process for determining the suitability for distribution of a batch of rivaroxaban or of a pharmaceutical composition thereof. In particular, it also relates to two impurities of rivaroxaban, to their use as reference markers to determine the purity of a sample of rivaroxaban or a composition thereof, to analytical methods for determining the purity of a sample of rivaroxaban or a composition thereof and to a process of preparing rivaroxaban or pharmaceutical compositions thereof which are free or substantially free of such impurities.